rophylaxis in surgical patients: a meta-analysis. Ann Surg
2017;265:1094-103.
253. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy
for VTE disease: second update of the CHEST guideline and expert
panel report. Chest 2021;160:e545-608.
254. Dua A, Heller JA, Patel B, Desai SS. Variability in the management of
superﬁcial venous thrombophlebitis across practitioners based in
north America and the global community. Thrombosis 2014;2014:
306018.
255. Prandoni P, Pesavento R, Bilora F, et al. No difference in outcome
between therapeutic and preventive anticoagulation in patients
with superﬁcial vein thrombosis involving the saphenous-femoral
junction. Vasc Med 2022;27:290-2.
256. Casian D, Bzovii F, Culiuc V, Gutu E. Urgent surgery versus anticoagulation for treatment of superﬁcial vein thrombosis in patients
with varicose veins. Vasa 2022;51:174-81.
257. Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of
thromboembolic complications in patients with superﬁcial-vein
thrombosis given rivaroxaban or fondaparinux: the open-label,
randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017;4:e105-13.
258. Superﬁcial Thrombophlebitis Treated By Enoxaparin Study G.
A pilot randomized double-blind comparison of a low-molecularweight heparin, a nonsteroidal anti-inﬂammatory agent, and placebo in the treatment of superﬁcial vein thrombosis. Arch Intern
Med 2003;163:1657-63.
259. Indom